

Journal Pre-proof

T cells in the skin: lymphoma and inflammatory skin disease

Ben Roediger, Christoph Schlapbach

PII: S0091-6749(22)00234-2

DOI: <https://doi.org/10.1016/j.jaci.2022.02.015>

Reference: YMAI 15478

To appear in: *Journal of Allergy and Clinical Immunology*

Received Date: 1 February 2022


Revised Date: 23 February 2022

Accepted Date: 23 February 2022

Please cite this article as: Roediger B, Schlapbach C, T cells in the skin: lymphoma and inflammatory skin disease, *Journal of Allergy and Clinical Immunology* (2022), doi: <https://doi.org/10.1016/j.jaci.2022.02.015>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.



1 T cells in the skin: lymphoma and inflammatory skin disease

2 Ben Roediger¹ and Christoph Schlapbach^{2*}

3

4 Affiliation

5 1) Translational Medicine, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland

6 2) Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Switzerland

7

8 *Correspondence to:

9 Christoph Schlapbach

10 Inselspital, Bern University Hospital, University of Bern, Switzerland

11 christoph.schlapbach@insel.ch

12

13

14 Word count: 4950

15 Number of references: 174

16

17

18 Conflict of interest

19 B.R. is a current employee of and holds company stocks with Novartis Pharma AG. C.S. has received honoraria as adviser for

20 Abbvie, LEO Pharma, Lilly, and Novartis and has received research funding from PPM Services/Nogra Pharma.

21 Abstract

22 T cells are established contributors to the pathogenesis of atopic dermatitis (AD) and psoriasis, yet whether they are the key
23 drivers or simply unwitting participants remains incompletely understood. Conversely, malignant T cells are the undisputed
24 culprits of cutaneous T cell lymphoma (CTCL), a group of diseases that share key clinical, histopathological and molecular
25 features with inflammatory skin disease (ISD). Here, we compare the pathogenesis of ISD and CTCL and discuss the resulting
26 insights. Recurrent, skin-limited disease implicates skin-resident T cells (T_{RM}) in both ISD and CTCL. In CTCL, malignant T cells
27 recruit benign T cells into inflammatory skin lesions, a disease-amplifying function also proposed for pathogenic T cells in ISD.
28 Mechanistically, cytokines produced by malignant T cells in CTCL and by pathogenic T cells in ISD, respectively, are likely both
29 necessary and sufficient to drive skin inflammation and pruritus, which in turn promotes skin barrier dysfunction and
30 dysbiosis. Therapies for ISD target T cell effector functions but do not address the chronicity of disease while treatments for
31 CTCL target malignant T cells but not primarily the symptoms of the disease. By integrating our understanding of ISD and
32 CTCL, important insights into pathogenesis and therapy can be made which may improve the lives of sufferers of both disease
33 groups.

34 1. What do we know?

- 35 • *ISD and CTCL share key clinical and molecular features and T cells are at the heart of pathogenesis in both disease*
 36 *groups*
- 37 • *ISD are increasingly well understood and amenable to targeted therapies whereas CTCL lacks efficient, let alone*
 38 *curative, therapeutic options.*
- 39 • *Comparative analysis of ISD and CTCL provides insight into the pathogenesis of both disease groups*

40 2. What is still unknown?

- 41 • *What is the role of T cell-derived cytokines in cutaneous manifestation and progression of CTCL? Can lessons from*
 42 *cytokine blockade in ISD be transferred to novel CTCL treatment approaches?*
- 43 • *Curative approaches in CTCL aim at eradicating malignant (skin-resident) T cells. Can similar approaches be applied*
 44 *to ISD with the aim of curing, rather than suppressing disease?*
- 45 • *In early stage CTCL, few clonal malignant T cells cause infiltration of large amounts of bystander T cells, which are*
 46 *necessary for clinical disease manifestation. Could a minor population of potentially auto-antigen-specific,*
 47 *pathogenic T cells cause disease in ISD via similar mechanisms as in CTCL?*
- 48 • *The signals and pathways that govern (pathogenic) T cell activation in ISD remain incompletely understood. Can*
 49 *insights into oncogenic signaling in malignant CTCL cells be transferred to pathogenic T cells in ISD to open up new*
 50 *therapeutic targets and opportunities?*

52 Abbreviations

53	AD	Atopic dermatitis
54	AHR	Aryl hydrocarbon receptor
55	CTCL	Cutaneous T cell lymphoma
56	DC	Dendritic cell
57	EATL	Enteropathy-associated T cell lymphoma
58	ISD	Inflammatory skin disease
59	JAK	Janus kinase
60	MALT	Mucosa-associated lymphoid tissue lymphoma
61	MAPK	Mitogen-activated protein kinase
62	MF	Mycosis fungoides
63	MMAE	Monomethyl auristatin E
64	PUVA	Psoralen plus UVA
65	scRNA-seq	Single cell RNA sequencing
66	SOCS	Suppressor of cytokine signaling
67	SS	Sézary Syndrome
68	STAT	Signal transducer and activator of transcription proteins
69	T _{CM}	Central memory T cell
70	TCR	T cell receptor
71	T _H 2	T helper type 2 cell
72	T _{RM}	Resident memory T cells
73	UVA	Ultraviolet light

74

75 Introduction

76 Chronic inflammatory skin diseases (ISDs) comprise a wide range of cutaneous disorders that clinically manifest in variable
77 combinations of erythema, plaques, scaling, pruritus, and pain. ISDs also accompany a variety of histopathological features,
78 including epidermal thickening, spongiosis, parakeratosis and, near universally, T cell infiltration. The two most common T
79 cell driven-ISDs are atopic dermatitis (AD) and psoriasis and, for the purposes of this review, ISD will refer to AD and psoriasis
80 unless otherwise specified. Cutaneous T cell lymphoma (CTCL) encompasses a similarly heterogeneous collection of T cell
81 malignancies of the skin. Arguably the best understood variants of CTCL are mycosis fungoides (MF) and Sézary syndrome
82 (SS), which have distinct and overlapping phenotypes that are discussed in this review. ISD and CTCL demonstrate striking
83 epidemiological, clinical, and molecular parallels and respond to similar treatments, despite being elicited by distinct causes.
84 Drawing comprehensive parallels between ISDs and CTCL generates important insights into the pathogenesis of both disease
85 groups that may both inform and inspire new therapeutic approaches.

86

87 Clinical, epidemiological, and genetic parallels between ISD and CTCL

88 Clinical parallels

89 ISD and CTCL, in particular MF, share many basic skin morphologies (Figure 1). Both may present as erythematous patches,
90 papules, and plaques, whereas only CTCL may develop skin tumors(1-3). Secondary morphologies may be eczematous or
91 papulosquamous in nature in both disease groups. Thus, AD and psoriasis are at the forefront of the clinical differential
92 diagnosis of MF. Erythrodermic CTCL, mostly caused by SS, may resemble primary or secondary erythroderma, which can also
93 be observed in both AD and psoriasis(4).

94 Certain clinical features are typical for CTCL and distinguish them from ISDs. For instance, CTCL patches may be
95 hypopigmented or hyperpigmented. Postlesional hyper- or hypopigmentation also occurs in ISD, but typically only after the
96 inflammatory component of the lesion has resolved. MF tends to occur in non-sun-exposed areas, which may help to
97 distinguish it from typical AD lesions on the flexor surfaces and typical psoriasis lesions on the extensor aspects of the knees
98 and elbows(1, 2). The clinical presentation of MF is generally more variable than that of chronic ISD and tends to change
99 morphology more substantially over the course of the disease (e.g. development of tumors and ulcerations).

100 In terms of symptoms, lesions from both CTCL and ISDs, in particular AD and other forms of eczema, are often pruritic
101 and pruritus is a key determinant of poor quality of life in both disease groups. Erythroderma in particular, either in SS or ISD,
102 is associated with agonizing pruritus(1, 2).

103

104 Epidemiological and genetic parallels between ISD and CTCL

105 Patients with a history of ISD have an increased risk of developing CTCL(5). Psoriasis patients in particular have a strongly
106 increased hazard ratio (up to HR >6)(6), but also severe AD is associated with non-Hodgkin-lymphoma, including CTCL(7,
107 8).Especially early stage CTCL can be misdiagnosed as ISD, given its clinical and histological similarities, and this might explain

108 part of the epidemiological connection. However, even when taking this bias into account, the epidemiological link remains
109 strong and prompts the search for additional explanations. These include common genetic background, chronic inflammatory
110 environment in the skin, and long-term side effects of ISD treatment, as discussed below.

111 The genetic background of both ISD and CTCL is increasingly well understood. Risk loci predisposing for psoriasis or
112 AD are enriched for genes related to keratinocyte differentiation, innate immune signaling, cytokine mediated signaling, and
113 T cell activation and differentiation(1, 9-11). Genetic alterations in CTCL comprise of copy number variations and single-
114 nucleotide variants that affect similar pathways, particularly T cell receptor (TCR) signaling and the nuclear factor kappa B
115 (NF- κ B) pathway, the MAP kinase pathway, and JAK-STAT signaling(3, 12). At the single gene level, CTCL shares genetic
116 alterations with both psoriasis and AD in the STAT3 gene (Figure 2). STAT3 is a key mediator of T cell responses to
117 interleukins(13), underscoring the importance of cytokines in the pathogenesis of both disease groups.

118 Another putative mechanistic link between ISD and CTCL is chronic inflammation. Chronic inflammation can act as
119 promotor of tumor development(14). Many cancers arise at sites of chronic infection or chronic inflammation(15), wherein
120 inflammatory cells are thought to establish a microenvironment that drives the neoplastic process. Interestingly, in some
121 murine models of CTCL, skin tumors only form in the setting of skin inflammation(16). Although the role of inflammation in
122 driving CTCL in humans remains incompletely understood, links have been more firmly established in other types of
123 lymphoma. Specifically, gastric mucosa-associated lymphoid tissue (MALT) lymphoma, an indolent B-cell NHL arising in
124 lymphoid infiltrates from *H. pylori* gastroduodenitis(17), and enteropathy-associated T cell lymphoma (EATL), a peripheral T
125 cell lymphoma (PTCL) derived from intestinal intraepithelial lymphocytes of patients with longstanding celiac disease(18). In
126 EATL, ongoing T cell activation and the inflammatory milieu in the intestinal epithelium causes the accumulation of genetic
127 alterations in pathways related to lymphoma development. These include genes involved in cytokine signaling (*JAK1*, *JAK3*,
128 *STAT3*, *STAT5B*, *SOCS1*), MAPK signaling (*BRAF*, *KRAS*), and chromatin modification (*CREBBP*), all of which are genetic
129 vulnerabilities also found in CTCL. As in the case of ISD and CTCL, EATL shares a genetic background with its underlying
130 inflammatory disease, celiac disease (e.g. variants in *TNFAIP3*)(18). Taken together, it is likely that ISD is linked to CTCL
131 pathogenesis by shared underlying genetics and chronic T cell-driven skin inflammation(17).

132

133 Pathogenetic parallels between CTCL and ISD

134 T cells as major culprits in CTCL and ISD

135 T cells are, by definition, the cause of cutaneous pathology in CTCL but they also play a central role in ISD(1-3). Indeed, the
136 capacity of malignant CTCL clones to recapitulate the full clinical picture and symptoms of eczema or psoriasis underscores
137 the remarkable pathogenic potential of dysregulated T cells in skin inflammation. Further evidence for a critical involvement
138 of T cells in ISD includes the efficacy of cyclosporine in its treatment(19-21) and the HLA-association of disease(22, 23).
139 Further, T cells make up a substantial part of the inflammatory infiltrate, their presence correlates with disease severity(24)
140 and targeting T cell-derived proinflammatory cytokines efficiently restores skin homeostasis in AD and psoriasis(1, 2).
141 Critically, a large body of animal research have demonstrated the sufficiency of T cells to drive AD- and psoriasis-like

142 phenotypes in mice and established cytokines as central to T cell effector function in inflammatory disease(25, 26). Thus, T
143 cells may be proposed as the critical node of ISD, regardless of underlying genetics and other pathogenetic factors such as
144 damage to the epithelium or skin dysbiosis(1-3).

145

146 Skin resident T cells in CTCL and ISD

147 Adult human skin harbors billions of nonrecirculating resident memory T (T_{RM}) cells(27, 28). Most T_{RM} in human skin are
148 dermal CD4+ T helper cells, while the epidermis contains both CD4+ and CD8+ T_{RM} . T_{RM} are generated as a consequence of
149 local skin infection, may persist in the absence of antigen, and provide rapid immune protection against local reinfection(29).
150 Both CD4+ and CD8+ T_{RM} are intricately linked to pathogenesis of both CTCL and ISD.

151 Translational studies in CTCL patients have led to a model in which malignant T cells in MF express a T_{RM} phenotype
152 and a skin-homing central memory (T_{CM}) phenotype in Sézary syndrome, respectively(28, 30). This model provides an elegant
153 explanation for key clinical observations. The skin-sessile T_{RM} phenotype of malignant MF cells explains why most patients
154 have skin-limited disease with well-demarcated, stable inflammatory skin lesions that resolve under topical therapy but recur
155 at the same location if treatment is stopped(28). Conversely, the T_{CM} phenotype of malignant T cells in SS allows them to
156 recirculate between the blood and skin, enter lymph nodes, and cause diffuse erythema of the skin, thus explaining the clinical
157 hallmarks of SS (i.e. diffuse erythema, blood and lymph node involvement). The T_{RM} - T_{CM} model further explains why MF is
158 primarily treated with skin-directed therapies whereas SS requires systemic treatment(31). However, this model does not
159 account for the extensive diversity and plasticity of malignant T cells in CTCL with respect to their surface marker expression,
160 maturation status, and function(32-34). Further, single cell analysis in MF patients suggest that malignant clones from skin
161 may switch from a T_{RM} phenotype to a T_{CM} phenotype when they leave the skin and enter lymph nodes or blood(35). This
162 indicates that malignant T cells are highly plastic and strongly respond to their microenvironment, a still understudied
163 phenomenon in human skin immunology. Translational studies in CTCL patients hold the potential to address this
164 phenomenon and to generate insights also applicable to ISD(35-37).

165 T_{RM} are also intricately linked to pathology in ISD, a prototypical example being psoriasis. Pathogenic T_{RM} cells exist
166 in lesional, non-lesional and post-lesional skin of psoriasis patients, and their aberrant activation causes disease(38, 39). Other
167 ISD in which T_{RM} play a key role include fixed drug eruption(40), allergic contact dermatitis(41), and AD(42, 43). As in the case
168 of MF, disease-causing T_{RM} would help explain why many skin lesions of ISD resolve with therapy but reoccur in the same
169 location once therapy is discontinued(29) or why patch-test reactions to contact allergens may flare-up in response to
170 systemic allergen exposure(44).

171 Therapeutic strategies aiming at curing rather than suppressing CTCL and ISD, respectively, will thus have to address
172 the longevity of pathogenic T_{RM} in the skin. Unless this population can be eradicated or fundamentally reprogrammed, disease
173 will likely relapse(45). A better understanding of the cell of origin of malignant T cells in CTCL and their response to
174 environmental cues will provide important insights into basic human T cell biology and spark new therapeutic developments
175 in ISD.

176

177 Pathogenic and bystander T cells in CTCL and ISD

178 A key unanswered question in ISD is the cause and nature of TCR activation. Both AD and psoriasis have been proposed to
179 be autoimmune diseases, but the identification of T cell autoantigens has proven challenging(46-48). It remains unclear
180 whether autoreactive T cells found in psoriasis and AD are the primary cause of disease or a secondary autoimmune
181 phenomenon as observed in other chronic inflammatory conditions(46, 49). T cells may also be responding to exogenous
182 antigens, particularly in AD, where T cell reactivity to bacterial antigens and allergens have been reported(46, 48).
183 Alternatively, disease-driving T cells in ISD might be activated without cognate antigens, an “innate” immune process known
184 as bystander T cell activation. Bystander T cell activation relies on cytokines and other nonspecific, T cell-extrinsic factors and
185 plays an important part in physiological immune responses, but also contributes to immunopathology(50, 51). Supportive of
186 a bystander-driven process are TCR repertoire studies of ISD patients that have repeatedly found more polyclonal T cells in
187 lesional AD and psoriatic skin compared to clinically resolved skin(42, 52, 53). Conversely, other studies have observed a more
188 restricted, oligoclonal TCR repertoire, particularly in psoriasis, suggestive of antigen-driven T cell activation(52, 54). However,
189 the lack of a consistent and dominant signature TCR repertoire across multiple patients and studies in ISD points to a relevant
190 role of bystander T cells in mediating skin inflammation in ISD.

191 To study bystander T cell activation in skin inflammation, the interplay between malignant T cell clones and benign
192 T cells in CTCL may provide additional insight. Of note, it has been established that clinically visible inflammation in CTCL is
193 dependent on activation of benign T cells, and that clinical improvement post therapy is linked to changes in the benign T cell
194 compartment, but not to malignant T cell reduction(55). This is additionally supported by recent scRNA-seq data
195 demonstrating the presence of phenotypically distinct CTCL clones in normal-appearing skin of patients with advanced-stage
196 MF(37). Thus, clinical manifestations of CTCL appear to be mostly mediated by bystander-activated T cells, as may be the case
197 in ISD(42, 52, 53). In CTCL, benign T cells are activated either by malignant T cell-derived cytokines or via immunological
198 synapses involving dendritic cells (DCs) and OX40-OX40L interactions(55, 56). DCs and OX40 signaling also contributes to T
199 cell activation in AD and psoriasis where therapeutics targeting of DC-T cell interactions are under clinical investigation(1, 57).
200 Whether in turn such immunological synapses provide survival signals to malignant T cells in CTCL or autoreactive T cell in
201 ISD, respectively, remains to be investigated.

202 In light of these recent insights, it may be time to revisit a major outstanding question remains regarding plasticity
203 of CTCL, particularly during disease progression. Historically, the differential detection of type 2 cytokines at different stages
204 led to the notion that a shift towards “type 2” was associated with malignancy(58). However, this theory is confounded by
205 the evidence that early CTCL is controlled, at least in part, by cytotoxic T cells as part of an immune surveillance, which is
206 diminished in later stages of disease(59). As such, the cytokine milieu changes with advancing CTCL can alternatively be seen
207 from the perspective of the bystander T cells, from an initial cytotoxic response that, as it becomes exhausted, “unmasks”
208 the intrinsic type 2 cytokine-driving nature of these cells. These competing hypotheses will be assessed/resolved through
209 detailed and longitudinal assessments of bystander and malignant T cells within the same patient at different stages of
210 disease.

211 If indeed a minor population of pathogenic T cells amplifies its effects via bystander T cell activation in both ISD and
212 CTCL, these cells and their products would be prime targets for therapeutic intervention. Such a view is reminiscent of the
213 concept of “pathogenic” versus “conventional” Th cell subsets, which posits that human inflammatory disease is caused by
214 distinct subpopulations of allergen- or autoantigen-specific pathogenic Th cells(60, 61). Both pathogenic T_{H17} (pT_{H17}) and
215 pathogenic T_{H2} cells (variably abbreviated pT_{H2} , T_{H2A} , T_{Hpath2}) have been described and are distinguished from their
216 conventional counterparts by unique differentiation requirements, surface phenotypes, and functional attributes(62-65).
217 Applying this concept to CTCL, malignant CD4+ T cells in MF might emulate pT_{H2} cells and act as orchestrators of skin
218 inflammation. In fact, there is an intriguing phenotypic overlap between malignant T cells, skin-resident T_{RM} from healthy
219 skin, and pT_{H2} cells(28, 30, 60, 66) (Table 1). These populations share expression of distinct cytokines (*IL13*, *IL22*), chemokine
220 receptors (*CCR4*), co-inhibitory receptors (*TIGIT*, *LGALS3*) and transcription factors (*TOX*)(35, 37, 60, 66, 67). Noteworthy, skin
221 T_{RM} with a T_{H2} phenotype remain elevated in formerly lesional skin of treated AD patients, consistent with a “pathogenic T
222 cell” designation(36). While the importance of this similarity remains to be elucidated, it suggests that CTCL cells, CD4+ T_{RM}
223 and pT_{H2} cells share a tissue-differentiation program. This program is likely the result of the skin microenvironment(60, 64)
224 and its disruption might prove a valuable therapeutic approach in both ISD and CTCL.

225

226 T cell-derived cytokines as key mediators in CTCL and ISD

227 Cytokines play a central pathogenic role in ISD, as evidenced by the impressive effect of cytokine blockade in psoriasis and
228 AD(1, 2). Most of these pathogenic cytokines are either produced directly by T cells (i.e. IL-13 and IL-31 in AD; IL-17A and IL-
229 17F in psoriasis) or act “upstream” and regulate pathogenic function via binding to receptors on T cells (i.e. IL-23 in psoriasis).
230 The cytokine(s) acting “upstream” of T_{H2} cells in AD, presuming they exist, have yet to be identified. Proposed cytokines
231 include IL-33, IL-25, TSLP, IL-1a and IL-18 (Figure 2) (68-72). T cells of varying subsets express receptors for these cytokines,
232 all of which can be produced in the skin(69), and trials blocking each of these cytokines in AD are ongoing. Collectively, these
233 observations firmly place T-cell-activating and T-cell-derived cytokines as central drivers of ISD.

234 Several questions regarding the involvement of cytokines in ISD remain. First, due to the transient nature of cytokine
235 expression in T cells and detection limitations, it is difficult to investigate the expression patterns and hence the involvement
236 of certain T cell-derived cytokines such as IL-2 or IL-4(73). Thus, their role must be inferred, primarily from clinical response
237 to cytokine blockade. For example, the apparently comparable Phase 3 response of AD to dupilumab(74) and lebrikizumab
238 (NCT04146363; NCT04178967) suggests that IL-13 is predominant over IL-4 in driving AD, but in the absence of head-to-head
239 trials this remains speculative. Moreover, the absence of IL-4 from AD skin, as observed in tissue transcriptomics studies(75),
240 does not rule out a role for this cytokine within secondary lymphoid organs, which may be promoting the expansion of
241 disease-driving T cells in ISD or of malignant clones in CTCL over the long-term. Second, questions remain as to whether
242 different cytokines act in additive, complementary or synergistic fashion. For example, do IL-13 and IL-31 act together to drive
243 AD and IL-17A with IL-17F to drive psoriasis? Or there are different endotypes of ISD, in which one cytokine predominates
244 over the other depending on the individual? Finally, additional T cell-derived cytokines of largely unknown function have been
245 identified in ISD, including GM-CSF, IL-24, IL-26 and IL-32(36, 75-78), but their contribution to disease remains largely

246 unexplored. While understanding the role of cytokines in ISD requires more investigation, current data collectively shows
247 that pathogenic T cells are the central drivers of ISD, and T cell-derived cytokines are likely both necessary and sufficient for
248 disease.

249 In CTCL, evidence suggests that malignant T cells use cytokines to foster an inflammatory and tumorigenic milieu
250 that mediate the clinical manifestation of CTCL(3, 79). Both early but especially advanced stages of CTCL are characterized by
251 a T_H2 bias, which is thought to be intrinsic to malignant T cells and then imposed on non-clonal benign T cells via T_H2
252 cytokines(56). The concept of a T_H2 bias in CTCL helps explain several pathological and clinical hallmarks of CTCL, including
253 impairment of skin barrier function, dysbiosis, propensity for infections, eczematous skin lesions, itch and eosinophilia(3, 79).
254 The central role of cytokines in mediating ISD further supports this notion and opens up new therapeutic avenues for CTCL
255 treatment. In particular, targeting of T_H2 cytokines such as IL-4, IL-13, and IL-31 appears promising. However, clinical
256 outcomes in CTCL patients treated with dupilumab are controversial. A number of case reports show progression of disease
257 under dupilumab(80-83), while others show control of itch and reversal of T_H2 bias(84-86). Further research is necessary to
258 better understand which cytokines should be targeted in CTCL and under which conditions. In addition to T_H2 cytokines,
259 cytokines such as IL-15(87, 88), IL-21(35), IL-22(89), IL-26(88), and IL-32(35, 88) might also serve as targets in CTCL.
260 However, cytokine blockade appears as an understudied opportunity in CTCL therapy, given the pivotal role of cytokines in
261 mediating signs and symptoms of skin disease, in shaping the tumor microenvironment, and in controlling T cell biology.

262

263 The skin microbiome in ISD and CTCL

264 The skin microbiome in ISD and CTCL shows considerable abnormalities and contributes to skin inflammation and clinical
265 burden in both. For instance, colonization with *Staphylococcus aureus* in lesional skin is associated with disease severity and
266 flares in both ISD and CTCL(1, 90, 91). Conversely, antiseptic or antibiotic treatments can improve clinical signs and symptoms
267 of AD and CTCL, respectively(92-95), strongly suggesting that the microbiome participates in driving or amplifying skin
268 inflammation. Shared host-microbiome interactions might thus be at play in ISD and CTCL. However, whether these
269 microbial abnormalities are secondary to epidermal barrier defects or secondary to skin inflammation remains unknown.
270 In AD, skin dysbiosis has been attributed to epithelial barrier defects caused by genetic deficiencies in structural proteins such
271 as filaggrin(96). However, genetic defects in skin barrier genes are unlikely the reason for dysbiosis in CTCL, as germline
272 mutations in skin barrier proteins are not enriched in CTCL patients(3) (Figure 1). Furthermore, the prevalence of atopy - a
273 proxy for genetic predisposition for epithelial barrier defects - in CTCL is comparable to that of the general population(97).
274 Thus, microbial dysbiosis in CTCL might be the direct consequence of malignant T cell-driven skin inflammation and a
275 dysregulated cutaneous T cell compartment appears to be sufficient to cause barrier dysfunction and consequent dysbiosis
276 in both CTCL and ISD. Indeed, lesional psoriasis skin shows similar downregulation as AD of key barrier proteins such as *FLG*,
277 and *LOR*, despite a lack of genetic association with these genes(98, 99) and topical steroids alone are capable of reducing *S.*
278 *aureus* colonization in lesional AD skin(100). In addition to inflammation, cutaneous immune deficiency caused by
279 dysregulated T cells might also contribute to dysbiosis, as patients with primary immunodeficiency commonly suffer from

280 skin disease, including AD, and this has been linked to microbial skin dysbiosis(101, 102). Overall, these observations in ISD
281 and CTCL underscore the central role of skin T cells in regulating epithelial barrier integrity and the skin microbiome.

282

283 T cell-driven pruritus in ISD and CTCL

284 The mechanisms of T cell-driven itch are incompletely understood, particularly in humans, but itch is largely considered to be
285 histamine-independent in ISD. Whether T cells produce classic ligands for direct activation of neurons (i.e. via ion channels or
286 GPCRs) has not been well explored, but the role of T cell-derived cytokines in driving itch has been firmly established(103). In
287 particular, IL-13 and IL-17 are clearly itch-drivers in AD and psoriasis, respectively, evidenced by the early reduction of itch
288 with anti-IL-4/13R and anti-IL-13 in AD and IL-17 blockade in psoriasis(104, 105). Of these, IL-13 would appear to be the most
289 potent mediator of itch, based on the higher intensity of itch in AD compared to psoriasis. Notably, dupilumab can also be
290 very effective at alleviating itch in CTCL(84). Collectively, these data strongly implicate T cell-derived IL-13 as a key mediator
291 of itch in CTCL and ISD.

292 The mechanism of cytokine-driven itch remains underexplored. One possibility is that inflammatory cytokines reduce
293 the threshold of activation of itch neurons. This has been demonstrated in mice for type 2 cytokine signaling, in which IL-4
294 potentiated a clinical response to a normally subclinical dose of histamine(106). But additional mechanistic explanations exist,
295 and the propensity of transgenic mice over-expressing cytokines to drive pruritus extends beyond IL-4 and IL-13(107, 108) to
296 include IL-22(109), IL-31(110), TSLP(111) and IL-18(112). How these cytokines elicit itch is not entirely clear. For IL-13, IL-31,
297 IL-17 and TSLP, the receptors are expressed by itch neurons, and a direct effect can be envisaged. Conversely, IL-18 and IL-23
298 likely cause itch indirectly via activation of T cells. How IL-22 overexpression leads to itch in mice remains even less clear,
299 since the IL-22 receptors are primarily expressed by keratinocytes. This observation, along with the partial response to anti-
300 IL-22 in AD patients(113), suggests a capacity of epidermal keratinocytes to directly drive itch. This is consistent with other
301 mouse models in which epidermally-confined genetic dysregulation that also evoke AD-like phenotypes(114-116), and is
302 indirectly supported by the GWAS associations of AD with epidermally-expressed genes(22). Collectively, these data raise the
303 prospect that T cell-derived cytokine-driven itch in ISD is not necessarily acting directly via itch neurons but may additionally
304 (or predominantly) act via keratinocytes and potentially other cells, including antigen presenting cells. These observations
305 also raise the prospect that other T cell- and CTCL-derived members of the IL-20 family may play a role in itch via the
306 keratinocyte, particularly IL-24 and IL-26.

307

308 Tissue and serum biomarkers of ISD and CTCL

309 Biomarkers serve important functions in clinical and research settings, informing prognosis and management at the patient
310 level as well as disease understanding in research and in clinical trials. Today, biomarkers are not mainstay tools in the
311 management of ISD or CTCL, but hold huge potential for better management of both. As biomarkers in ISD have been
312 comprehensively reviewed elsewhere(117, 118), we focus here on selected biomarkers and potential learnings from CTCL.

313 **Tissue biomarkers.** In ISD, tissue biopsies are not routinely stained for markers, although biopsies are regularly taken
314 to confirm diagnosis. In contrast, CTCL biopsies are stained for various molecules of interest, including CD3, CD4, CD30, Ki67
315 and TIA1. These biomarkers are not yet relevant for management of ISD but may inform research endeavors. For example,
316 CD30 is a maker of T cell activation, and shown to be elevated on pT_H2 cells in AD(60), meaning that it could be integrated
317 into CITE-sequencing(119) or spatial sequencing(120) experiments to identify activated T cells vs bystander T cells in ISD.
318 Similarly, TIA1 is a likely marker of activated CD8 T cells, is upregulated in psoriasis(121) and lichen planus(122), and may help
319 delineate CD8 involvement in ISD and CD8+ MF.

320 **Systemic biomarkers.** The most validated blood biomarkers in ISD are molecules which are produced in large
321 quantities in response to inflammatory cytokines, such that they are sufficiently abundant to diffuse from the skin to the
322 blood. In the context of clinical trials ISD, two of the most validated biomarkers are CCL17 (TARC) in AD and beta-defensin 2
323 (BD-2; DEFB4B) in psoriasis, which serve as simultaneous biomarkers of cytokine signaling (type 2 and type 17, respectively)
324 and disease burden(123, 124). CCL17 is also elevated in CTCL(125), consistent with the T_H2 bias in CTCL, and might serve to
325 monitor therapy success and repolarization of the tumor microenvironment towards an anti-tumor type 1 milieu.

326 In CTCL, systemic biomarker endeavors focus on identifying the malignant clones using flow cytometry, an approach
327 greatly aided by the advancements in multiparametric flow cytometry(126). Future assessments in ISD may similarly focus on
328 the pathogenic T cells, particularly if the therapeutic intervention is aimed at reducing or eliminating them.. Multiparametric
329 flow cytometry in PBMCs from ISD patients identified specific T cell subsets changes unique to AD relative to healthy
330 volunteers and psoriasis patients, which highlight potential assays for monitoring disease response(127).

331 **Endotyping.** On the premise that the better defined the patient, the more effectively one can treat their disease,
332 there are ongoing endeavors to identify the different endotypes of disease and their distinct response to treatment. While
333 plaque psoriasis is relatively homogeneous disease with high response rates to blockade of a single cytokine (e.g. IL-17 or IL-
334 23), the subgrouping of AD patients into clinically meaningful endotypes has remained elusive. Historically, AD has been
335 grouped into “extrinsic” (presence of allergy) and “intrinsic” (no atopy), with serum IgE serving as the molecular arbiter of
336 the two(128). Later, molecular markers such as the presence of a FLG mutation have been introduced. , however no clear
337 relationship to therapy response has been found so far. More recently, there have been efforts to endotype AD
338 biochemically(129, 130), with one group reporting 4 AD subgroups based on serum proteins(131). Yet, how all these
339 endotypes relate to treatment response remains largely unknown(132, 133). The question remains whether non-responders
340 to a targeted therapy (e.g. cytokine blockade) comprise a definable subgroup or whether they merely sit at the more severe
341 end of a spectrum of disease, possibly driven by quantitative variations in cytokine levels but otherwise clinically
342 indistinguishable. Further research in ISD endotyping is needed and will likely lead to a deeper cellular and molecular
343 understanding of the pathogenic T cells, both in the circulation and within the skin. From this, lessons may be transferrable
344 to clinical subtyping and biomarker development in CTCL.

345

346 Therapeutic consequences

347 Following the success of cytokine blockade in ISD, dozens of drugs are being evaluated as potential therapeutics in ISD, the
348 most progressed of which are anti-cytokine antibodies and JAK inhibitors(1, 2). Psoriasis has seen the advancement of
349 particularly efficacious therapies in the form of anti-IL-17 and anti-IL-23 antibodies and our therapeutic armamentarium is
350 even further expanded with the advent of oral allosteric TYK2 inhibitors (e.g. deucravacitinib)(2). In contrast, in AD, there has
351 yet to be an antibody that demonstrates superiority over dupilumab, and the (conventional, non-allosteric) JAK inhibitors,
352 while effective, accompany safety concerns. Additional, early-stage therapeutics in AD seek to interfere with T cell re-
353 circulation (e.g sphingosine-1-phosphate receptor 1 modulators; NCT04162769; NCT04684485), skin homing (CCR4 inhibitor;
354 NCT04271514), or T cell activation, either directly (anti-OX40L-antibody; NCT05131477) or via Treg expansion (IL-2 conjugate;
355 NCT04081350). Nevertheless, none of these ISD therapies are expected to eliminate the pathogenic T cells. The following ISD
356 therapies might conceptually be applied to CTCL:

357 **JAK inhibitors:** Based on the genetic alterations in CTCL, JAK inhibition appears promising. In malignant T cells, the
358 JAK-STAT pathway is constitutively active regardless of whether its constituents are affected by mutations(134). Inhibition of
359 the JAK-STAT pathway leads to apoptosis of CTCL cells *in vitro*(135, 136) and to sensitization to other drugs such as histone
360 deacetylase inhibitors.(137) Yet, it is difficult to predict the clinical efficacy and long-term effects of JAK inhibitors in CTCL, as
361 they are likely to impact the anti-tumor immune response and may trigger escape mutations. Topical JAK inhibitors(138) may
362 potentially impact skin T_{RM} survival and thus malignant T cell survival in MF, based on the potentially critical role for common
363 gamma chain signaling in maintenance of memory T cells(139).

364 **Aryl hydrocarbon receptor (AHR) modulators**(140, 141): Topical AHR modulators may potentially impact T_{RM}
365 survival in the skin, based on their effects on human and murine T cells *in vitro*(142).

366 **Anti-OX40L-antibody:** In CTCL, T cell activation via immunological synapses involving DCs and OX40-OX40L have
367 been proposed to provide tumorigenic signals(55, 56). Thus, the anti-OX40L monoclonal Antibody (KY1005) being developed
368 in AD might prove beneficial in CTCL as well.

369 **CCR4 inhibitor:** RPT193 is an oral small molecule CCR4 antagonist under clinical trials in AD. It is thought to block
370 recruitment of T_{H2} cells into and retention of T_{RM} in skin. Given the important expression of CCR4 on malignant T cells(28)
371 and the solid clinical efficacy of the anti-CCR4 antibody mogamulizumab in CTCL, application of CCR4 inhibitors in CTCL
372 appears promising.

373 In contrast to therapies in ISD, therapies for CTCL ultimately aim at eliminating the cancerous T cells, particularly in later
374 stages of disease. A wide variety of topical, physical, and systemic therapies are used in CTCL, the vast majority of which lack
375 curative potential(3). Some insights from CTCL therapy studies are, however, of interest for therapeutic development in ISD
376 as well.

377 **PUVA:** In psoralen plus ultraviolet A (UVA) light (PUVA) therapy, patients ingest or topically apply 8-methoxypsoralen
378 and then are exposed to UVA light. PUVA is an effective treatment for MF and for ISDs including psoriasis and AD, albeit with
379 the risk of inducing non-melanoma skin cancer(143). Interestingly, PUVA is capable of eradicated malignant T cells in low-

380 burden MF patients(55), suggesting that chemo-phototherapy regimens might be adapted for curative approaches in ISD,
381 aiming to deplete the pathogenic T cells in lesional skin.

382 **Anti-CD52 (alemtuzumab):** T cell-depleting antibody that is effective but accompany significant risk of infection,
383 autoimmune reactions and other side effects.

384 **Anti-CD30 (Brentuximab vedotin):** An antibody-drug conjugate, in which anti-CD30 has been linked to Monomethyl
385 auristatin E (MMAE), a potent anti-mitotic compound, for the depletion of CD30+ T cell lymphoma cells, including CTCL(144).
386 MMAE has been conjugated to other antibodies for the treatment of pancreatic, breast, ovarian and urothelial cancers, as
387 well as B cell malignancies, and is often associated with toxicities (most notably peripheral neuropathy) irrespective of the
388 antibody it is conjugated to(145).

389 **Anti-CCR4 (mogamulizumab):** An afucosylated monoclonal antibody for enhanced antibody-dependent cellular
390 cytotoxicity of CTCL cells in both MF and SS(146). The afucosylation may overcome the challenge of tissue-level depletion of
391 T cells reported in alemtuzumab-treated patients(28). Clinical response is likely augmented by the concomitant depletion of
392 CCR4+ regulatory T cells (i.e. an immuno-oncology-mediated effect), which accompanies toxicity (most frequently skin
393 rashes)(147).

394 Currently, there is a dichotomy between therapies for ISD that aim to suppress T cell-driven inflammation versus
395 therapies for CTCL that seek to eliminate the cause of disease. However, both disease spheres might profit from one another,
396 with cross-fertilization of pathogenetic concepts and therapeutic approaches becoming more and more relevant as our
397 understanding of the diseases grows. Although the toxicity profile of current, broad-acting anti-T cell antibodies makes them
398 poorly suited for ISD, they nevertheless demonstrate the feasibility of T cell elimination as a therapeutic option, which can
399 be expected to evolve with time. Additional potential strategies for directly targeting T cells include radioligand therapy(148),
400 antibody-siRNA conjugates(149), CD3 bi-specific antibodies(150), CAR T cells(151), drugs targeting T cell metabolism(152) and
401 transcription factor inhibition, including novel STAT3-degraders(153). As our capacity to target malignant and pathogenic T
402 cells become safer and more refined, they will raise the inexorable question: Instead of merely treating CTCL and ISD, can we
403 cure it?

404

405 References

- 406 - 1. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nat Rev Dis Primers*.
407 2018;4(1):1.
- 408 - 2. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. *Lancet*. 2021;397(10281):1301-15.
- 409 - 3. Dummer R, Vermeer MH, Scarisbrick JJ, Kim YH, Stonesifer C, Tensen CP, et al. Cutaneous T cell
410 lymphoma. *Nat Rev Dis Primers*. 2021;7(1):61.
- 411 - 4. Inamadar AC, Ragnatha S. The rash that becomes an erythroderma. *Clin Dermatol*. 2019;37(2):88-98.
- 412 - 5. Phan A, Veldman R, Lechowicz MJ. T-cell Lymphoma Epidemiology: the Known and Unknown. *Curr*
413 *Hematol Malig Rep*. 2016;11(6):492-503.
- 414 - 6. Bellinato F, Gisondi P, Girolomoni G. Risk of lymphohematologic malignancies in patients with chronic
415 plaque psoriasis: A systematic review with meta-analysis. *Journal of the American Academy of Dermatology*. 2021.
- 416 - 7. Legendre L, Barnette T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients
417 with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis. *J Am Acad Dermatol*.
418 2015;72(6):992-1002.
- 419 - 8. Mansfield KE, Schmidt SAJ, Darvalics B, Mulick A, Abuabara K, Wong AYS, et al. Association Between
420 Atopic Eczema and Cancer in England and Denmark. *JAMA Dermatol*. 2020;156(10):1086-97.
- 421 - 9. Singh S, Pradhan D, Puri P, Ramesh V, Aggarwal S, Nayek A, et al. Genomic alterations driving psoriasis
422 pathogenesis. *Gene*. 2019;683:61-71.
- 423 - 10. Dand N, Mahil SK, Capon F, Smith CH, Simpson MA, Barker JN. Psoriasis and Genetics. *Acta Derm*
424 *Venereol*. 2020;100(3):adv00030.
- 425 - 11. Paternoster L, Standl M, Waage J, Baurecht H, Hotze M, Strachan DP, et al. Multi-ancestry genome-wide
426 association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. *Nat Genet*.
427 2015;47(12):1449-56.
- 428 - 12. Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, et al. Genomic analysis of 220 CTCLs
429 identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). *Blood*. 2017;130(12):1430-40.
- 430 - 13. Wei L, Laurence A, O'Shea JJ. New insights into the roles of Stat5a/b and Stat3 in T cell development and
431 differentiation. *Semin Cell Dev Biol*. 2008;19(4):394-400.
- 432 - 14. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet?
433 *Science*. 2013;339(6117):286-91.
- 434 - 15. Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer
435 immunotherapy. *Nat Rev Cancer*. 2019;19(6):307-25.
- 436 - 16. Wu X, Sells RE, Hwang ST. Upregulation of inflammatory cytokines and oncogenic signal pathways
437 preceding tumor formation in a murine model of T-cell lymphoma in skin. *J Invest Dermatol*. 2011;131(8):1727-34.
- 438 - 17. Marcelis L, Tousseyn T, Sagaert X. MALT Lymphoma as a Model of Chronic Inflammation-Induced Gastric
439 Tumor Development. *Curr Top Microbiol Immunol*. 2019;421:77-106.
- 440 - 18. Chander U, Leeman-Neill RJ, Bhagat G. Pathogenesis of Enteropathy-Associated T Cell Lymphoma. *Curr*
441 *Hematol Malig Rep*. 2018;13(4):308-17.
- 442 - 19. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Buijnzeel-Koomen CA. Enteric-
443 coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis:
444 a randomized controlled trial. *J Am Acad Dermatol*. 2011;64(6):1074-84.
- 445 - 20. Goujon C, Viguier M, Staumont-Salle D, Bernier C, Guillet G, Lahfa M, et al. Methotrexate Versus
446 Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial. *J Allergy Clin*
447 *Immunol Pract*. 2018;6(2):562-9 e3.
- 448 - 21. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type
449 psoriasis. Results of a multidose, double-blind trial. *N Engl J Med*. 1991;324(5):277-84.
- 450 - 22. Grosche S, Marenholz I, Esparza-Gordillo J, Arnau-Soler A, Pairo-Castineira E, Ruschendorf F, et al. Rare
451 variant analysis in eczema identifies exonic variants in DUSP1, NOTCH4 and SLC9A4. *Nat Commun*. 2021;12(1):6618.
- 452 - 23. Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. *J Dermatol Sci*. 2020;99(1):2-8.
- 453 - 24. Ungar B, Garcet S, Gonzalez J, Dhingra N, Correa da Rosa J, Shemer A, et al. An Integrated Model of Atopic
454 Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. *J Invest Dermatol*. 2017;137(3):603-13.

- 455 - 25. Gangwar RS, Gudjonsson JE, Ward NL. Mouse Models of Psoriasis: A Comprehensive Review. *J Invest*
456 *Dermatol.* 2021.
- 457 - 26. Gilhar A, Reich K, Keren A, Kabashima K, Steinhoff M, Paus R. Mouse models of atopic dermatitis: a critical
458 reappraisal. *Exp Dermatol.* 2021;30(3):319-36.
- 459 - 27. Watanabe R, Gehad A, Yang C, Scott LL, Teague JE, Schlapbach C, et al. Human skin is protected by four
460 functionally and phenotypically discrete populations of resident and recirculating memory T cells. *Sci Transl Med.*
461 2015;7(279):279ra39.
- 462 - 28. Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin effector memory T cells do
463 not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. *Sci Transl Med.* 2012;4(117):117ra7.
- 464 - 29. Clark RA. Resident memory T cells in human health and disease. *Sci Transl Med.* 2015;7(269):269rv1.
- 465 - 30. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct
466 T-cell subsets: a biologic rationale for their distinct clinical behaviors. *Blood.* 2010;116(5):767-71.
- 467 - 31. Mehta-Shah N, Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, et al. NCCN Guidelines Insights: Primary
468 Cutaneous Lymphomas, Version 2.2020. *J Natl Compr Canc Netw.* 2020;18(5):522-36.
- 469 - 32. Moins-Teisserenc H, Daubord M, Clave E, Douay C, Felix J, Marie-Cardine A, et al. CD158k is a reliable
470 marker for diagnosis of Sezary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. *J Invest*
471 *Dermatol.* 2015;135(1):247-57.
- 472 - 33. Roelens M, Delord M, Ram-Wolff C, Marie-Cardine A, Alberdi A, Maki G, et al. Circulating and skin-derived
473 Sezary cells: clonal but with phenotypic plasticity. *Blood.* 2017;130(12):1468-71.
- 474 - 34. Buus TB, Willerslev-Olsen A, Fredholm S, Blumel E, Nastasi C, Glud M, et al. Single-cell heterogeneity in
475 Sezary syndrome. *Blood Adv.* 2018;2(16):2115-26.
- 476 - 35. Rindler K, Bauer WM, Jonak C, Wielscher M, Shaw LE, Rojahn TB, et al. Single-Cell RNA Sequencing Reveals
477 Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells. *Front Immunol.* 2021;12:666935.
- 478 - 36. Bangert C, Rindler K, Krausgruber T, Alkon N, Thaler FM, Kurz H, et al. Persistence of mature dendritic
479 cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4Ralpha blockade. *Sci Immunol.*
480 2021;6(55).
- 481 - 37. Rindler K, Jonak C, Alkon N, Thaler FM, Kurz H, Shaw LE, et al. Single-cell RNA sequencing reveals markers
482 of disease progression in primary cutaneous T-cell lymphoma. *Mol Cancer.* 2021;20(1):124.
- 483 - 38. Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in
484 a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. *J Exp Med.*
485 2004;199(5):731-6.
- 486 - 39. Boyman O, Conrad C, Tonel G, Gilliet M, Nestle FO. The pathogenic role of tissue-resident immune cells in
487 psoriasis. *Trends Immunol.* 2007;28(2):51-7.
- 488 - 40. Shiohara T, Mizukawa Y. The immunological basis of lichenoid tissue reaction. *Autoimmun Rev.*
489 2005;4(4):236-41.
- 490 - 41. Gaide O, Emerson RO, Jiang X, Gulati N, Nizza S, Desmarais C, et al. Common clonal origin of central and
491 resident memory T cells following skin immunization. *Nat Med.* 2015;21(6):647-53.
- 492 - 42. Brunner PM, Emerson RO, Tipton C, Garcet S, Khattri S, Coats I, et al. Nonlesional atopic dermatitis skin
493 shares similar T-cell clones with lesional tissues. *Allergy.* 2017;72(12):2017-25.
- 494 - 43. Sun Z, Kim JH, Kim SH, Kim HR, Zhang K, Pan Y, et al. Skin-resident natural killer T cells participate in
495 cutaneous allergic inflammation in atopic dermatitis. *J Allergy Clin Immunol.* 2021;147(5):1764-77.
- 496 - 44. Hindsen M, Bruze M, Christensen OB. Flare-up reactions after oral challenge with nickel in relation to
497 challenge dose and intensity and time of previous patch test reactions. *J Am Acad Dermatol.* 2001;44(4):616-23.
- 498 - 45. Divito SJ, Aasebo AT, Matos TR, Hsieh PC, Collin M, Elco CP, et al. Peripheral host T cells survive
499 hematopoietic stem cell transplantation and promote graft-versus-host disease. *J Clin Invest.* 2020;130(9):4624-36.
- 500 - 46. Roesner LM, Werfel T. Autoimmunity (or Not) in Atopic Dermatitis. *Front Immunol.* 2019;10:2128.
- 501 - 47. Prinz JC. Autoimmune aspects of psoriasis: Heritability and autoantigens. *Autoimmun Rev.*
502 2017;16(9):970-9.
- 503 - 48. Ten Bergen LL, Petrovic A, Aarebrot AK, Appel S. Current knowledge on autoantigens and autoantibodies
504 in psoriasis. *Scand J Immunol.* 2020;92(4):e12945.
- 505 - 49. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for
506 immunotherapy. *Nat Rev Immunol.* 2002;2(2):85-95.

- 507 - 50. Lee H, Jeong S, Shin EC. Significance of bystander T cell activation in microbial infection. *Nat Immunol.* 2022;23(1):13-22.
- 508
- 509 - 51. Guo L, Huang Y, Chen X, Hu-Li J, Urban JF, Jr., Paul WE. Innate immunological function of TH2 cells in vivo. *Nat Immunol.* 2015;16(10):1051-9.
- 510
- 511 - 52. Matos TR, O'Malley JT, Lowry EL, Hamm D, Kirsch IR, Robins HS, et al. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing alphabeta T cell clones. *J Clin Invest.* 2017;127(11):4031-41.
- 512
- 513 - 53. Harden JL, Hamm D, Gulati N, Lowes MA, Krueger JG. Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis. *F1000Res.* 2015;4:460.
- 514
- 515 - 54. Merleev AA, Marusina AI, Ma C, Elder JT, Tsoi LC, Raychaudhuri SP, et al. Meta-analysis of RNA sequencing datasets reveals an association between TRAJ23, psoriasis, and IL-17A. *JCI Insight.* 2018;3(13).
- 516
- 517 - 55. Vieyra-Garcia P, Crouch JD, O'Malley JT, Seger EW, Yang CH, Teague JE, et al. Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. *JCI Insight.* 2019;4(1).
- 518
- 519 - 56. Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. *Clin Cancer Res.* 2013;19(14):3755-63.
- 520
- 521
- 522 - 57. Papp KA, Gooderham MJ, Girard G, Raman M, Strout V. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. *J Eur Acad Dermatol Venereol.* 2017;31(8):1324-32.
- 523
- 524
- 525 - 58. Vowels BR, Lessin SR, Cassin M, Jaworsky C, Benoit B, Wolfe JT, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. *J Invest Dermatol.* 1994;103(5):669-73.
- 526
- 527 - 59. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. *J Am Acad Dermatol.* 1995;32(3):448-53.
- 528
- 529 - 60. Bertschi NL, Bazzini C, Schlapbach C. The Concept of Pathogenic TH2 Cells: Collegium Internationale Allergologicum Update 2021. *Int Arch Allergy Immunol.* 2021;182(5):365-80.
- 530
- 531 - 61. Schnell A, Huang L, Singer M, Singaraju A, Barilla RM, Regan BML, et al. Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity. *Cell.* 2021;184(26):6281-98 e23.
- 532
- 533 - 62. Stockinger B, Omenetti S. The dichotomous nature of T helper 17 cells. *Nat Rev Immunol.* 2017;17(9):535-534
- 534
- 535 - 63. Wambre E, Bajzik V, DeLong JH, O'Brien K, Nguyen QA, Speake C, et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. *Sci Transl Med.* 2017;9(401).
- 536
- 537 - 64. Micosse C, von Meyenn L, Steck O, Kipfer E, Adam C, Simillion C, et al. Human "TH9" cells are a subpopulation of PPAR-gamma(+) TH2 cells. *Sci Immunol.* 2019;4(31).
- 538
- 539 - 65. Hirahara K, Aoki A, Kiuchi M, Nakayama T. Memory-type pathogenic TH2 cells and ILC2s in type 2 allergic inflammation. *J Allergy Clin Immunol.* 2021;147(6):2063-6.
- 540
- 541 - 66. Klicznik MM, Morawski PA, Hollbacher B, Varkhande SR, Motley SJ, Kuri-Cervantes L, et al. Human CD4(+)CD103(+) cutaneous resident memory T cells are found in the circulation of healthy individuals. *Sci Immunol.* 2019;4(37).
- 542
- 543
- 544 - 67. Jonak C, Alkon N, Rindler K, Rojahn TB, Shaw LE, Porkert S, et al. Single-cell RNA sequencing profiling in a patient with discordant primary cutaneous B-cell and T-cell lymphoma reveals micromilieu-driven immune skewing. *Br J Dermatol.* 2021;185(5):1013-25.
- 545
- 546
- 547 - 68. Cevikbas F, Steinhoff M. IL-33: a novel danger signal system in atopic dermatitis. *J Invest Dermatol.* 2012;132(5):1326-9.
- 548
- 549 - 69. Honda T, Kabashima K. Reconciling innate and acquired immunity in atopic dermatitis. *J Allergy Clin Immunol.* 2020;145(4):1136-7.
- 550
- 551 - 70. Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? *J Invest Dermatol.* 2011;131(1):150-7.
- 552
- 553 - 71. Van Den Eeckhout B, Tavernier J, Gerlo S. Interleukin-1 as Innate Mediator of T Cell Immunity. *Front Immunol.* 2020;11:621931.
- 554
- 555 - 72. Ziegler SF, Roan F, Bell BD, Stoklasek TA, Kitajima M, Han H. The biology of thymic stromal lymphopoietin (TSLP). *Adv Pharmacol.* 2013;66:129-55.
- 556
- 557 - 73. Sojka DK, Bruniquel D, Schwartz RH, Singh NJ. IL-2 secretion by CD4+ T cells in vivo is rapid, transient, and influenced by TCR-specific competition. *J Immunol.* 2004;172(10):6136-43.
- 558

- 559 - 74. Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with
560 moderate-to-severe atopic dermatitis. *N Engl J Med.* 2014;371(2):130-9.
- 561 - 75. Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic Dermatitis Is an IL-13-
562 Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. *J Invest Dermatol.* 2019;139(7):1480-9.
- 563 - 76. He H, Suryawanshi H, Morozov P, Gay-Mimbrera J, Del Duca E, Kim HJ, et al. Single-cell transcriptome
564 analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. *J*
565 *Allergy Clin Immunol.* 2020;145(6):1615-28.
- 566 - 77. Reynolds G, Vegh P, Fletcher J, Poyner EFM, Stephenson E, Goh I, et al. Developmental cell programs are
567 co-opted in inflammatory skin disease. *Science.* 2021;371(6527).
- 568 - 78. Rojahn TB, Vorstandlechner V, Krausgruber T, Bauer WM, Alkon N, Bangert C, et al. Single-cell
569 transcriptomics combined with interstitial fluid proteomics defines cell type-specific immune regulation in atopic
570 dermatitis. *J Allergy Clin Immunol.* 2020;146(5):1056-69.
- 571 - 79. Patil K, Kuttikrishnan S, Khan AQ, Ahmad F, Alam M, Buddenkotte J, et al. Molecular pathogenesis of
572 Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways. *Semin Cancer Biol.* 2021.
- 573 - 80. Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of
574 cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients. *J Am Acad Dermatol.* 2020;83(1):197-9.
- 575 - 81. Tran J, Morris L, Vu A, Duvic M. Development of Sezary syndrome following the administration of
576 dupilumab. *Dermatol Online J.* 2020;26(4).
- 577 - 82. Poyner EFM, Bacon CM, Osborne W, Frew JA, Weatherhead SC. Dupilumab unmasking cutaneous T-cell
578 lymphoma; report of a fatal case. *Clin Exp Dermatol.* 2021.
- 579 - 83. Russomanno K, Carver DeKlotz CM. Acceleration of cutaneous T-cell lymphoma following dupilumab
580 administration. *JAAD Case Rep.* 2021;8:83-5.
- 581 - 84. Steck O, Bertschi NL, Luther F, van den Berg J, Winkel DJ, Holbro A, et al. Rapid and sustained control of
582 itch and reduction in Th2 bias by dupilumab in a patient with Sezary syndrome. *J Eur Acad Dermatol Venereol.*
583 *2021;35(6):1331-7.*
- 584 - 85. Lazaridou I, Ram-Wolff C, Bouaziz JD, Begon E, Battistella M, Rivet J, et al. Dupilumab Treatment in Two
585 Patients with Cutaneous T-cell Lymphomas. *Acta Derm Venereol.* 2020;100(16):adv00271.
- 586 - 86. Mollanazar NK, Savage KT, Pousti BT, Jariwala N, Del Guzzo C, Haun P, et al. Cutaneous T-cell lymphoma
587 and concomitant atopic dermatitis responding to dupilumab. *Cutis.* 2020;106(3):131-2.
- 588 - 87. Adachi T, Kobayashi T, Sugihara E, Yamada T, Ikuta K, Pittaluga S, et al. Hair follicle-derived IL-7 and IL-15
589 mediate skin-resident memory T cell homeostasis and lymphoma. *Nat Med.* 2015;21(11):1272-9.
- 590 - 88. Litvinov IV, Tetzlaff MT, Thibault P, Gangar P, Moreau L, Watters AK, et al. Gene expression analysis in
591 Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.
592 *Oncoimmunology.* 2017;6(5):e1306618.
- 593 - 89. Miyagaki T, Sugaya M, Suga H, Kamata M, Ohmatsu H, Fujita H, et al. IL-22, but not IL-17, dominant
594 environment in cutaneous T-cell lymphoma. *Clin Cancer Res.* 2011;17(24):7529-38.
- 595 - 90. Langan EA, Griffiths CEM, Solbach W, Knobloch JK, Zillikens D, Thaci D. The role of the microbiome in
596 psoriasis: moving from disease description to treatment selection? *Br J Dermatol.* 2018;178(5):1020-7.
- 597 - 91. Durgin JS, Weiner DM, Wysocka M, Rook AH. The immunopathogenesis and immunotherapy of cutaneous
598 T cell lymphoma: Pathways and targets for immune restoration and tumor eradication. *J Am Acad Dermatol.*
599 *2021;84(3):587-95.*
- 600 - 92. Huang JT, Rademaker A, Paller AS. Dilute bleach baths for *Staphylococcus aureus* colonization in atopic
601 dermatitis to decrease disease severity. *Arch Dermatol.* 2011;147(2):246-7.
- 602 - 93. Lewis DJ, Holder BB, Duvic M. The "Duvic regimen" for erythrodermic flares secondary to *Staphylococcus*
603 *aureus* in mycosis fungoides and Sezary syndrome. *Int J Dermatol.* 2018;57(1):123-4.
- 604 - 94. Lindahl LM, Willerslev-Olsen A, Gjerdrum LMR, Nielsen PR, Blumel E, Rittig AH, et al. Antibiotics inhibit
605 tumor and disease activity in cutaneous T-cell lymphoma. *Blood.* 2019;134(13):1072-83.
- 606 - 95. Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic
607 dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. *J Am*
608 *Acad Dermatol.* 2017;77(4):623-33.
- 609 - 96. Baurecht H, Ruhlemann MC, Rodriguez E, Thielking F, Harder I, Erkens AS, et al. Epidermal lipid
610 composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. *J Allergy*
611 *Clin Immunol.* 2018;141(5):1668-76 e16.

- 612 - 97. Mehrany K, El-Azhary RA, Bouwhuis SA, Pittelkow MR. Cutaneous T-cell lymphoma and atopy: is there an
613 association? *Br J Dermatol*. 2003;149(5):1013-7.
- 614 - 98. Weichenthal M, Ruether A, Schreiber S, Nair R, Voorhees JJ, Schwarz T, et al. Filaggrin R501X and
615 2282del4 mutations are not associated with chronic plaque-type psoriasis in a German cohort. *J Invest Dermatol*.
616 2007;127(6):1535-7.
- 617 - 99. Zhao Y, Terron-Kwiatkowski A, Liao H, Lee SP, Allen MH, Hull PR, et al. Filaggrin null alleles are not
618 associated with psoriasis. *J Invest Dermatol*. 2007;127(8):1878-82.
- 619 - 100. Nilsson EJ, Henning CG, Magnusson J. Topical corticosteroids and *Staphylococcus aureus* in atopic
620 dermatitis. *J Am Acad Dermatol*. 1992;27(1):29-34.
- 621 - 101. de Wit J, Brada RJK, van Veldhuizen J, Dalm V, Pasmans S. Skin disorders are prominent features in
622 primary immunodeficiency diseases: A systematic overview of current data. *Allergy*. 2019;74(3):464-82.
- 623 - 102. Oh J, Freeman AF, Program NCS, Park M, Sokolic R, Candotti F, et al. The altered landscape of the human
624 skin microbiome in patients with primary immunodeficiencies. *Genome Res*. 2013;23(12):2103-14.
- 625 - 103. Wang F, Kim BS. Itch: A Paradigm of Neuroimmune Crosstalk. *Immunity*. 2020;52(5):753-66.
- 626 - 104. Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, et al. Efficacy and Safety of
627 Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b
628 Randomized Clinical Trial. *JAMA Dermatol*. 2020;156(4):411-20.
- 629 - 105. Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, et al. Secukinumab improves patient-
630 reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical
631 trials. *Int J Dermatol*. 2016;55(4):401-7.
- 632 - 106. Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory Neurons Co-opt Classical Immune
633 Signaling Pathways to Mediate Chronic Itch. *Cell*. 2017;171(1):217-28 e13.
- 634 - 107. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a
635 pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. *J Invest Dermatol*.
636 2001;117(4):977-83.
- 637 - 108. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of interleukin-13 in the skin
638 induces a pruritic dermatitis and skin remodeling. *J Invest Dermatol*. 2009;129(3):742-51.
- 639 - 109. Lou H, Lu J, Choi EB, Oh MH, Jeong M, Barmettler S, et al. Expression of IL-22 in the Skin Causes Th2-
640 Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway.
641 *J Immunol*. 2017;198(7):2543-55.
- 642 - 110. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31,
643 a cytokine produced by activated T cells, induces dermatitis in mice. *Nat Immunol*. 2004;5(7):752-60.
- 644 - 111. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, et al. Spontaneous atopic dermatitis in mice
645 expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. *J Exp Med*. 2005;202(4):541-9.
- 646 - 112. Konishi H, Tsutsui H, Murakami T, Yumikura-Futatsugi S, Yamanaka K, Tanaka M, et al. IL-18 contributes to
647 the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific
648 pathogen-free conditions. *Proc Natl Acad Sci U S A*. 2002;99(17):11340-5.
- 649 - 113. Brunner PM, Pavel AB, Khattri S, Leonard A, Malik K, Rose S, et al. Baseline IL-22 expression in patients
650 with atopic dermatitis stratifies tissue responses to fezakinumab. *J Allergy Clin Immunol*. 2019;143(1):142-54.
- 651 - 114. Hidaka T, Ogawa E, Kobayashi EH, Suzuki T, Funayama R, Nagashima T, et al. The aryl hydrocarbon
652 receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. *Nat Immunol*.
653 2017;18(1):64-73.
- 654 - 115. Kobayashi T, Glatz M, Horiuchi K, Kawasaki H, Akiyama H, Kaplan DH, et al. Dysbiosis and *Staphylococcus*
655 *aureus* Colonization Drives Inflammation in Atopic Dermatitis. *Immunity*. 2015;42(4):756-66.
- 656 - 116. Uluckan O, Jimenez M, Roediger B, Schnabl J, Diez-Cordova LT, Troule K, et al. Cutaneous Immune Cell-
657 Microbiota Interactions Are Controlled by Epidermal JunB/AP-1. *Cell Rep*. 2019;29(4):844-59 e3.
- 658 - 117. Magee C, Jethwa H, FitzGerald OM, Jadon DR. Biomarkers predictive of treatment response in psoriasis
659 and psoriatic arthritis: a systematic review. *Ther Adv Musculoskelet Dis*. 2021;13:1759720X211014010.
- 660 - 118. Renert-Yuval Y, Thyssen JP, Bissonnette R, Bieber T, Kabashima K, Hijnen D, et al. Biomarkers in atopic
661 dermatitis-a review on behalf of the International Eczema Council. *J Allergy Clin Immunol*. 2021;147(4):1174-90 e1.
- 662 - 119. Stoeckius M, Hafemeister C, Stephenson W, Houck-Loomis B, Chattopadhyay PK, Swerdlow H, et al.
663 Simultaneous epitope and transcriptome measurement in single cells. *Nat Methods*. 2017;14(9):865-8.

- 664 - 120. Salmen F, Stahl PL, Mollbrink A, Navarro JF, Vickovic S, Frisen J, et al. Barcoded solid-phase RNA capture
665 for Spatial Transcriptomics profiling in mammalian tissue sections. *Nat Protoc.* 2018;13(11):2501-34.
- 666 - 121. Austin LM, Coven TR, Bhardwaj N, Steinman R, Krueger JG. Intraepidermal lymphocytes in psoriatic lesions
667 are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. *J Cutan Pathol.* 1998;25(2):79-88.
- 668 - 122. Santoro A, Majorana A, Bardellini E, Festa S, Sapelli P, Facchetti F. NF-kappaB expression in oral and
669 cutaneous lichen planus. *J Pathol.* 2003;201(3):466-72.
- 670 - 123. Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, et al. Dupilumab suppresses type 2
671 inflammatory biomarkers across multiple atopic, allergic diseases. *Clin Exp Allergy.* 2021;51(7):915-31.
- 672 - 124. Kolbinger F, Loesche C, Valentin MA, Jiang X, Cheng Y, Jarvis P, et al. beta-Defensin 2 is a responsive
673 biomarker of IL-17A-driven skin pathology in patients with psoriasis. *J Allergy Clin Immunol.* 2017;139(3):923-32 e8.
- 674 - 125. Kakinuma T, Sugaya M, Nakamura K, Kaneko F, Wakugawa M, Matsushima K, et al. Thymus and
675 activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of
676 mycosis fungoides. *J Am Acad Dermatol.* 2003;48(1):23-30.
- 677 - 126. Najidh S, Tensen CP, van der Sluijs-Gelling AJ, Teodosio C, Cats D, Mei H, et al. Improved Sezary cell
678 detection and novel insights into immunophenotypic and molecular heterogeneity in Sezary syndrome. *Blood.*
679 2021;138(24):2539-54.
- 680 - 127. Farrera C, Melchioti R, Petrov N, Weng Teng KW, Wong MT, Loh CY, et al. T-cell phenotyping uncovers
681 systemic features of atopic dermatitis and psoriasis. *J Allergy Clin Immunol.* 2020;145(3):1021-5 e15.
- 682 - 128. Tokura Y. Extrinsic and intrinsic types of atopic dermatitis. *J Dermatol Sci.* 2010;58(1):1-7.
- 683 - 129. Leonard A, Wang J, Yu L, Liu H, Estrada Y, Greenlees L, et al. Atopic Dermatitis Endotypes Based on
684 Allergen Sensitization, Reactivity to Staphylococcus aureus Antigens, and Underlying Systemic Inflammation. *J Allergy Clin*
685 *Immunol Pract.* 2020;8(1):236-47 e3.
- 686 - 130. Leung DYM, Calatroni A, Zaramela LS, LeBeau PK, Dyjack N, Brar K, et al. The nonlesional skin surface
687 distinguishes atopic dermatitis with food allergy as a unique endotype. *Sci Transl Med.* 2019;11(480).
- 688 - 131. Bakker DS, Nierkens S, Knol EF, Giovannone B, Delemarre EM, van der Schaft J, et al. Confirmation of
689 multiple endotypes in atopic dermatitis based on serum biomarkers. *J Allergy Clin Immunol.* 2021;147(1):189-98.
- 690 - 132. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for
691 targeted therapeutics. *J Allergy Clin Immunol.* 2019;143(1):1-11.
- 692 - 133. Guttman-Yassky E, Bissonnette R, Ungar B, Suarez-Farinas M, Ardeleanu M, Esaki H, et al. Dupilumab
693 progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. *J Allergy Clin Immunol.*
694 2019;143(1):155-72.
- 695 - 134. Waldmann TA, Chen J. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications
696 for Immunotherapy. *Annu Rev Immunol.* 2017;35:533-50.
- 697 - 135. van der Fits L, Out-Luiting JJ, Tensen CP, Zoutman WH, Vermeer MH. Exploring the IL-21-STAT3 axis as
698 therapeutic target for Sezary syndrome. *J Invest Dermatol.* 2014;134(10):2639-47.
- 699 - 136. van Kester MS, Out-Luiting JJ, von dem Borne PA, Willemze R, Tensen CP, Vermeer MH. Cucurbitacin I
700 inhibits Stat3 and induces apoptosis in Sezary cells. *J Invest Dermatol.* 2008;128(7):1691-5.
- 701 - 137. Cortes JR, Patrone CC, Quinn SA, Gu Y, Sanchez-Martin M, Mackey A, et al. Jak-STAT Inhibition Mediates
702 Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma. *J Invest Dermatol.* 2021;141(12):2908-20 e7.
- 703 - 138. Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. *J Allergy Clin Immunol.*
704 2021;148(4):927-40.
- 705 - 139. Surh CD, Sprent J. Homeostasis of naive and memory T cells. *Immunity.* 2008;29(6):848-62.
- 706 - 140. Paller AS, Stein Gold L, Soung J, Tallman AM, Rubenstein DS, Gooderham M. Efficacy and patient-reported
707 outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with
708 atopic dermatitis. *J Am Acad Dermatol.* 2021;84(3):632-8.
- 709 - 141. Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, et al. Phase 3 Trials of Tapinarof
710 Cream for Plaque Psoriasis. *N Engl J Med.* 2021;385(24):2219-29.
- 711 - 142. Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, et al. Tapinarof Is a Natural AhR
712 Agonist that Resolves Skin Inflammation in Mice and Humans. *J Invest Dermatol.* 2017;137(10):2110-9.
- 713 - 143. Vieyra-Garcia PA, Wolf P. A deep dive into UV-based phototherapy: Mechanisms of action and emerging
714 molecular targets in inflammation and cancer. *Pharmacol Ther.* 2021;222:107784.

- 715 - 144. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and
716 Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome - Update 2017.
717 *Eur J Cancer*. 2017;77:57-74.
- 718 - 145. Best RL, LaPointe NE, Azarenko O, Miller H, Genualdi C, Chih S, et al. Microtubule and tubulin binding and
719 regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE):
720 Mechanistic insights into MMAE ADC peripheral neuropathy. *Toxicol Appl Pharmacol*. 2021;421:115534.
- 721 - 146. Kim YH, Bagot M, Eradat HA, Carson KR, Greer JP, Kim EJ, et al. Phase 3 study of anti-CCR4 monoclonal
722 antibody mogamulizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL). *Journal of Clinical*
723 *Oncology*. 2014;32(15_suppl):TPS8623-TPS.
- 724 - 147. Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, Ito A, et al. Robust CD8+ T-cell proliferation and
725 diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma. *Blood Adv*. 2020;4(10):2180-91.
- 726 - 148. Lapa C, Hanscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA, et al. Feasibility of CXCR4-Directed
727 Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma. *J Nucl Med*. 2019;60(1):60-4.
- 728 - 149. Tushir-Singh J. Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy. *Expert*
729 *Opin Biol Ther*. 2017;17(3):325-38.
- 730 - 150. Paul S, Pearlman AH, Douglass J, Mog BJ, Hsiue EH, Hwang MS, et al. TCR beta chain-directed bispecific
731 antibodies for the treatment of T cell cancers. *Sci Transl Med*. 2021;13(584).
- 732 - 151. Scarfo I, Frigault MJ, Maus MV. CAR-Based Approaches to Cutaneous T-Cell Lymphoma. *Front Oncol*.
733 2019;9:259.
- 734 - 152. von Meyenn L, Bertschi NL, Schlapbach C. Targeting T Cell Metabolism in Inflammatory Skin Disease. *Front*
735 *Immunol*. 2019;10:2285.
- 736 - 153. Zhou H, Bai L, Xu R, McEachern D, Chinnaswamy K, Li R, et al. SD-91 as A Potent and Selective STAT3
737 Degradable Capable of Achieving Complete and Long-Lasting Tumor Regression. *ACS Med Chem Lett*. 2021;12(6):996-1004.
- 738 - 154. Clark RA, Schlapbach C. TH9 cells in skin disorders. *Semin Immunopathol*. 2017;39(1):47-54.
- 739 - 155. Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova E, Teague JE, et al. Human TH9 cells are skin-tropic
740 and have autocrine and paracrine proinflammatory capacity. *Sci Transl Med*. 2014;6(219):219ra8.
- 741 - 156. Vieyra-Garcia PA, Wei T, Naym DG, Fredholm S, Fink-Puches R, Cerroni L, et al. STAT3/5-Dependent IL9
742 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides. *Clin Cancer Res*. 2016;22(13):3328-39.
- 743 - 157. Kumar S, Dharnija B, Marathe S, Ghosh S, Dwivedi A, Karulkar A, et al. The Th9 Axis Reduces the Oxidative
744 Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients. *Mol Cancer Res*.
745 2020;18(4):657-68.
- 746 - 158. Joller N, Lozano E, Burkett PR, Patel B, Xiao S, Zhu C, et al. Treg cells expressing the coinhibitory molecule
747 TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. *Immunity*. 2014;40(4):569-81.
- 748 - 159. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized
749 Functions in Immune Regulation. *Immunity*. 2016;44(5):989-1004.
- 750 - 160. Kourepini E, Paschalidis N, Simoes DC, Aggelakopoulou M, Grogan JL, Panoutsakopoulou V. TIGIT
751 Enhances Antigen-Specific Th2 Recall Responses and Allergic Disease. *J Immunol*. 2016;196(9):3570-80.
- 752 - 161. Anzengruber F, Ignatova D, Schlaepfer T, Chang YT, French LE, Pascolo S, et al. Divergent LAG-3 versus
753 BTLA, TIGIT, and FCRL3 expression in Sezary syndrome. *Leuk Lymphoma*. 2019;60(8):1899-907.
- 754 - 162. Thode C, Woetmann A, Wandall HH, Carlsson MC, Qvortrup K, Kauczok CS, et al. Malignant T cells secrete
755 galectins and induce epidermal hyperproliferation and disorganized stratification in a skin model of cutaneous T-cell
756 lymphoma. *J Invest Dermatol*. 2015;135(1):238-46.
- 757 - 163. Strobl J, Pandey RV, Krausgruber T, Bayer N, Kleissl L, Reininger B, et al. Long-term skin-resident memory T
758 cells proliferate in situ and are involved in human graft-versus-host disease. *Sci Transl Med*. 2020;12(570).
- 759 - 164. Giordano M, Croci DO, Rabinovich GA. Galectins in hematological malignancies. *Curr Opin Hematol*.
760 2013;20(4):327-35.
- 761 - 165. Campbell JJ, O'Connell DJ, Wurbel MA. Cutting Edge: Chemokine receptor CCR4 is necessary for antigen-
762 driven cutaneous accumulation of CD4 T cells under physiological conditions. *J Immunol*. 2007;178(6):3358-62.
- 763 - 166. Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. *Int Immunol*. 2015;27(1):11-20.
- 764 - 167. Islam SA, Chang DS, Colvin RA, Byrne MH, McCully ML, Moser B, et al. Mouse CCL8, a CCR8 agonist,
765 promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells. *Nat Immunol*. 2011;12(2):167-77.
- 766 - 168. Mobus L, Rodriguez E, Harder I, Stolzl D, Boraczynski N, Gerdes S, et al. Atopic dermatitis displays stable
767 and dynamic skin transcriptome signatures. *J Allergy Clin Immunol*. 2021;147(1):213-23.

- 768 - 169. Miyagaki T, Sugaya M, Suga H, Ohmatsu H, Fujita H, Asano Y, et al. Increased CCL18 expression in patients
769 with cutaneous T-cell lymphoma: association with disease severity and prognosis. *J Eur Acad Dermatol Venereol.*
770 2013;27(1):e60-7.
- 771 - 170. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. *Allergy.*
772 2020;75(1):54-62.
- 773 - 171. Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma
774 cells and regulates their proliferation. *Blood.* 2015;125(18):2798-805.
- 775 - 172. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation
776 and induces proinflammatory gene expression and migration of human keratinocytes. *J Immunol.* 2005;174(6):3695-702.
- 777 - 173. Eyerich K, Dimartino V, Cavani A. IL-17 and IL-22 in immunity: Driving protection and pathology. *Eur J*
778 *Immunol.* 2017;47(4):607-14.
- 779 - 174. Scott AC, Dundar F, Zumbo P, Chandran SS, Klebanoff CA, Shakiba M, et al. TOX is a critical regulator of
780 tumour-specific T cell differentiation. *Nature.* 2019;571(7764):270-4.
- 781 - 175. Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining 'T cell exhaustion'. *Nat Rev*
782 *Immunol.* 2019;19(11):665-74.
- 783 - 176. Huang Y, Su MW, Jiang X, Zhou Y. Evidence of an oncogenic role of aberrant TOX activation in cutaneous
784 T-cell lymphoma. *Blood.* 2015;125(9):1435-43.
- 785 - 177. Xu J, Huang H, Wang S, Chen Y, Yin X, Zhang X, et al. Molecular profiling of TOX-deficient neoplastic cells in
786 cutaneous T cell lymphoma. *Arch Dermatol Res.* 2020;312(7):513-25.

787

788

789 Table 1: Genes commonly expressed by pathogenic T_H2, T_{RM}, and malignant CTCL cells

Category	Gene	Name	Role in type 2 inflammation	Putative role in CTCL
Cytokine receptor	IL9R	Interleukin 9 receptor (CD129)	<ul style="list-style-type: none"> - IL-9R signaling promotes survival, proliferation and cytokine production in T_H2 cells(63, 154, 155) 	<ul style="list-style-type: none"> - May promote tumor cell growth(156, 157) - May inhibit anti-tumor immunity(156, 157)
Surface receptors	TIGIT	T cell immunoreceptor with Ig and ITIM domains	<ul style="list-style-type: none"> - Inhibitory receptor on T cells(158, 159) - Ligation enhances Th2 function(160) 	<ul style="list-style-type: none"> - May promote Th2 bias in malignant T cells while suppressing anti-tumor immunity(161)
	LGALS3	Galectin 3	<ul style="list-style-type: none"> - Induces keratinocyte hyperproliferation(162) - May promote long-term survival of T_{RM}(163) 	<ul style="list-style-type: none"> - May participates in epithelial barrier disruption(162) - May promote chemoresistance to genotoxic agents(164)
Chemokine receptor	CCR4	CC chemokine receptor 4	<ul style="list-style-type: none"> - Ligand for CCL17 and critical for skin-homing and skin-residency of T cells(165) - Highly expressed on Th2 and Treg cells(166) 	<ul style="list-style-type: none"> - CCL17-CCR4 interactions may promote epidermotropism of malignant T cells(166) - CCR4+ Treg cells may suppress cancer immunity
	CCR8	CC chemokine receptor 8	<ul style="list-style-type: none"> - CCR8+ T_H2 cells express high levels of cytokines and are pathogenic in models of type 2 skin inflammation(167) - CCL18 (ligand of CCR8) is highly upregulated in AD(75, 168) 	<ul style="list-style-type: none"> - CCL18 expression correlates with disease severity in CTCL(169) - CCR8-CCL18 interactions recruit Th2 cells into CTCL lesions(55)
Cytokines	IL9	Interleukin 9	<ul style="list-style-type: none"> - Autocrine/paracrine growth and activation factor for Th2 cells(63, 154) - Induces secretion of proinflammatory mediators by mast cells(154) 	<ul style="list-style-type: none"> - Promotes tumor cell growth(156, 157) - Inhibits anti-tumor immunity(156, 157)
	IL13	Interleukin 13	<ul style="list-style-type: none"> - promotes skin barrier disruption, immune cell recruitment, itch, and tissue remodeling(170) 	<ul style="list-style-type: none"> - promotes skin barrier disruption, immune cell recruitment, itch, and tissue remodeling - may function as autocrine/paracrine growth factor in malignant T cells(171)
	IL22	Interleukin 22	<ul style="list-style-type: none"> - inhibits epidermal differentiation(172) - promotes recruitment of immune cells(172) - promotes tissue remodeling(173) 	<ul style="list-style-type: none"> - Promotes epidermal hyperplasia and migration of CCR6+ cells such as Langerhans cells into lesional skin(89) - May promote tissue remodeling(173)
Transcriptional regulator	TOX	Thymocyte selection associated high mobility group box	<ul style="list-style-type: none"> - Induces transcriptional program associated with T cell exhaustion(174) - Prevents TCR overstimulation of T cells and activation-induced cell(175) - Highly expressed in skin T_{RM} 	<ul style="list-style-type: none"> - may promote TCR-signal independent survival and prevent apoptosis in malignant T cells(176) - may promote malignant T cell metabolism via mTORC1 activation(177)

792

793

794

FIGURE LEGEND

795 **Figure 1: Clinical presentation of selected cases of cutaneous T cell lymphoma, atopic dermatitis, and**
796 **psoriasis.**

797 **Overlapping clinical features between CTCL, psoriasis, and atopic dermatitis**

798 (A, B) Plaque psoriasis. (C, D) Plaque-type mycosis fungoides. (E) Atopic dermatitis. (F) Allergic contact eczema
799 (G, H) Patch- and plaque-type mycosis fungoides. (I) Eczematous plaque of mycosis fungoides

800

801

802 **Figure 2: Genetic alterations in CTCL and susceptibility loci associated with atopic dermatitis or psoriasis.**

803 Venn diagram intersecting genes found to be mutated in CTCL(3) (blue) with genes associated with psoriasis⁹⁻¹¹
804 (green) and atopic dermatitis(1) (red) by GWAS.

805

806 **Figure 3: Signaling pathways that regulate inflammatory cytokine production by pathogenic and malignant T**
807 **cells in ISD and CTCL.**

808 Cytokine expression is controlled by signaling through NF- κ B inducers (magenta), the JAK-STAT pathways (red),
809 and via TCR signaling (light blue). In CTCL, mutations within these pathways bypass the requirement for external
810 signals.

811

Psoriasis

CTCL

Atopic Dermatitis

CTCL



CTCL

psoriasis

